Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III rAd-IFN plus celecoxib and gemcitabine versus celecoxib and gemcitabine in previously treated malignant pleural mesothelioma
NL-OMON48042Phase 3Withdrawn
- Sponsor
- Trizell GmbH
- Start
- Jul 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pleural mesothelioma comparing nadofaragene firadenovec + celecoxib + gemcitabine with celecoxib + gemcitabine (2 arms). Primary endpoint: overall survival. Planned start Jul 2019; status: withdrawn.
02
Drugs
nadofaragene firadenoveccelecoxibgemcitabine
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON48042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48042.